Abstract
Background Patients with hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) exhibit structural and functional cardiac abnormalities. We aimed to identify imaging biomarkers for pre-clinical cardiomyopathy in healthy individuals carrying cardiomyopathy-associated variants (G+).
Methods We included 40,169 UK biobank participants without cardiac disease who had cardiac magnetic resonance imaging (CMR) measurements and whole exome sequencing. We first validated 22 CMR measurements by associating them with incident atrial fibrillation (AF) or heart failure (HF). We subsequently assessed associations of these measurements with HCM or DCM G+, or specific genes, utilising generalised linear models conditional on cardiac risk factors.
Results Thirteen CMR measurements were associated with incident AF and fifteen with HF. These included left-ventricular (LV) ejection fraction (EF) (hazard ratio [HR] 0.61, 95% confidence interval [95%CI] 0.54; 0.69) for HF and indexed maximum left atrial volume (LA-Vi max; HR1.47, 95%CI 1.29; 1.67) for AF. Five measurements associated with HCM G+, amongst which right ventricular (RV) end-systolic volume (RV-ESV; OR 0.62, 95%CI 0.53; 0.74), RV-EF (OR 1.36, 95%CI 1.19; 1.55), and right atrial EF (OR 1.22, 95%CI 1.08; 1.39). All associations overlapping with incident disease and HCM had opposite effect directions, such as RV-ESV with HF (OR 1.22, 95%CI 1.07; 1.40). Two CMR measurements associated with DCM G+: LV-ESVi (OR 1.35, 95%CI 1.15; 1.58) and LV-EF (OR 0.75, 95%CI 0.64; 0.88). Due to heterogeneity, we explored associations with individual cardiomyopathy genes, finding MAPSE associated with TTN and TNNT2, and LA pump and RA-EF associated with MYH7.
Conclusion We identified right heart CMR measurements associated with HCM G+ in healthy individuals, indicating early compensation of cardiac function. LV measurements were associated with DCM G+, where the CMR associations varied across individual DCM genes, suggesting distinct early pathophysiology.
Competing Interest Statement
AFS has received funding from New Amsterdam Pharma for unrelated projects. PMC is founder, CEO and shareholder of DGTL Health B.V. FWA is supported by UCL Hospitals NIHR Biomedical Research Centre. RK is an Associate Editor of JAMA. He receives support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (under awards R01HL167858 and K23HL153775), the Doris Duke Charitable Foundation (under award 2022060), and the Blavatnik Family Foundation. He also receives research support, through Yale, from Bristol-Myers Squibb, Novo Nordisk, and BridgeBio. He is a coinventor of U.S. Pending Patent Applications 63/562,335, 63/177,117, 63/428,569, 63/346,610, 63/484,426, 63/508,315, and 63/606,203. He is a co-founder of Ensight-AI, Inc. and Evidence2Health, health platforms to improve cardiovascular diagnosis and evidence-based cardiovascular care.
Funding Statement
PC is supported by University of Amsterdam Research Priority Agenda Program AI for Health Decision-Making. MvV is supported by a postdoc talent grant from the Amsterdam Cardiovascular Sciences. AFS is supported by BHF grant PG/22/10989, the UCL BHF Research Accelerator AA/18/6/34223, and the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre. CRB was funded by the European Innovation Council Pathfinder Programme (DCM-NEXT project). This work was funded by UK Research and Innovation (UKRI) under the UK government's Horizon Europe funding guarantee EP/Z000211/1. This work received funding from the European Union's Horizon Europe research and innovation programme under Grant Agreement No. 101057849 (DataTools4Heart project) and No. 101080430 (AI4HF project). This publication is part of the project “Computational medicine for cardiac disease” with file number 2023.022 of the research programme “Computing Time on National Computer Facilities” which is (partly) financed by the Dutch Research Council (NWO).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for the UKB study was obtained from the North West Centre for Research Ethics Committee (11/NW/0382) and all participants provided informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All scripts and aggregated data are available online at “URL available upon publication”.
Non-standard abbreviations and acronyms
- AF
- atrial fibrillation
- CMP
- cardiomyopathy
- CMR
- cardiac magnetic resonance imaging
- DL
- deep learning
- DCM
- dilated cardiomyopathy
- EDV
- end-diastolic volume
- EF
- ejection fraction
- ESV
- end-systolic volume
- GWAS
- genome-wide association study
- G+
- individuals carrying disease-associated variants
- HCM
- hypertrophic cardiomyopathy
- HF
- heart failure
- HR
- hazard ratio
- i
- indexed
- IQR
- interquartile range
- LA
- left atrial
- LV
- left ventricular
- MAPSE
- mitral annular plane systolic excursion
- OR
- odds ratio
- Pump
- pump volume
- RA
- right atrial
- Res
- reservoir volume
- RV
- right ventricular
- SV
- stroke volume
- TAPSE
- tricuspid annular plane systolic excursion
- V max
- maximal volume
- V min
- minimal volume
- WES
- whole exome sequencing
- 2Ch
- 2-chamber
- 4Ch
- 4-chamber
- 95%CI
- 95% confidence interval
